September 20, 2022 08:45 AM EDTUpdated September 22, 09:46 AM
Bioregnum

Join me in Boston to­day to meet biotech's top star­tups

We’re putting the fin­ish­ing touch­es to this year’s End­points 11, our an­nu­al spe­cial re­port look­ing at some of the top up-and-com­ing pri­vate biotechs in the …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Judge halts some NIH cuts af­ter 22 states sue

Mer­ck KGaA con­firms in­ter­est in ac­quir­ing can­cer biotech Spring­Works

Decade af­ter $8B deal, Roche of­floads In­ter­Mune to mys­te­ri­ous spe­cial­ty phar­ma

Eli Lil­ly inks $630M deal for Phase 1 MASH can­di­date

Boehringer In­gel­heim touts suc­cess in sec­ond Phase 3 lung fi­bro­sis tri­al

sponsored

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

A service from the Financial Times